Halozyme Therapeutics

Aktuelle Nachrichten

Schlagzeilen in der Originalsprache der Quelle.

• Unpacking Q2 Earnings: Halozyme Therapeutics (NASDAQ:HALO) In The Context Of Other Therapeutics Stocks (öffnet in neuem Tab)

  Yahoo Finance · 01.10.2026

• Argus raises target for Halozyme Therapeutics stock to USD 127 (öffnet in neuem Tab)

  AD HOC NEWS · 01.10.2026

• Halozyme Therapeutics Adds James Daly to Board (öffnet in neuem Tab)

  tipranks.com · 30.09.2026

• Halozyme appoints Jim Daly to board of directors By Investing.com (öffnet in neuem Tab)

  Investing.com Nigeria · 30.09.2026

• Halozyme adds James Daly to its Board of Directors (öffnet in neuem Tab)

  TradingView · 30.09.2026

• Halozyme Therapeutics, Inc. Appoints James "Jim" Daly to Its Board of Directors (öffnet in neuem Tab)

  marketscreener.com · 30.09.2026

• Halozyme Announces Appointment of Jim Daly to its Board of Directors (öffnet in neuem Tab)

  PR Newswire · 30.09.2026

• Basic earnings per share (basic EPS) of Halozyme Therapeutics, Inc. – HAN:RV7 (öffnet in neuem Tab)

  TradingView · 29.09.2026

• Halozyme Therapeutics, Inc. Actuals & Estimates (HAN:RV7) (öffnet in neuem Tab)

  TradingView · 29.09.2026

• ETFs Investing in Halozyme Therapeutics, Inc. Stocks (öffnet in neuem Tab)

  TradingView · 29.09.2026

• Halozyme Therapeutics (HALO) Closes A US$1.3b Note Offering, Is The Upside Already Priced In? (öffnet in neuem Tab)

  Simply Wall Street · 24.09.2026

• Halozyme stock falls 2.34% after strong quarterly growth (öffnet in neuem Tab)

  AD HOC NEWS · 23.09.2026

• Strength Seen in Halozyme Therapeutics (HALO): Can Its 3.3% Jump Turn into More Strength? (öffnet in neuem Tab)

  Yahoo Finance · 23.09.2026

• If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now (öffnet in neuem Tab)

  Yahoo Finance · 23.09.2026

• Form 8K Halozyme Therapeutics Inc For: 22 September By Investing.com (öffnet in neuem Tab)

  Investing.com India · 22.09.2026

• Halozyme Therapeutics completes $1.5 billion convertible notes offering (öffnet in neuem Tab)

  Investing.com · 22.09.2026

• Halozyme (HALO) Just Made A $1.3B Bet On Itself (öffnet in neuem Tab)

  Yahoo Finance · 21.09.2026

• Halozyme Therapeutics stock edges higher as investors weigh Q2 growth and pipeline risk (öffnet in neuem Tab)

  AD HOC NEWS · 20.09.2026

• Halozyme Therapeutics (HALO) Proposes $1.05B in Convertibles. Is More Time Worth the Cost? (öffnet in neuem Tab)

  Yahoo Finance · 20.09.2026

• Should Enlarged Notes Sale Require Action From Halozyme Therapeutics (HALO) Investors? (öffnet in neuem Tab)

  Simply Wall Street · 19.09.2026

• Halozyme prices $1.3B of 1.50% convertible notes due 2033, upsized with $200M option (öffnet in neuem Tab)

  TradingView · 18.09.2026

• Dynatrace, Cava Group, Halozyme Therapeutics (öffnet in neuem Tab)

  TradingView · 18.09.2026

• Halozyme Prices $1.3 Billion Convertible Senior Notes Offering (öffnet in neuem Tab)

  Yahoo Finance · 18.09.2026

• Halozyme Therapeutics stock hits all-time high at 111.56 USD (öffnet in neuem Tab)

  Investing.com · 18.09.2026

• Halozyme Therapeutics, Inc. (NASDAQ:HALO) Prices Upsized $1.3B 1.50% Convertible Notes Due 2033 (öffnet in neuem Tab)

  TradingView · 17.09.2026

• Halozyme prices $1.3B convertible notes to fund repurchases and growth initiatives (öffnet in neuem Tab)

  Pluang · 17.09.2026

• Halozyme prices $1.3B convertible senior notes offering due 2033 (öffnet in neuem Tab)

  TradingView · 17.09.2026

• Halozyme prices $1.3 billion convertible notes offering (öffnet in neuem Tab)

  Investing.com · 17.09.2026

• Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033 (öffnet in neuem Tab)

  PR Newswire · 17.09.2026

• Is Halozyme Therapeutics (HALO) Fully Valued As Growth Calls And Partnerships Draw Fresh Attention? (öffnet in neuem Tab)

  Simply Wall Street · 17.09.2026